A LEADING INNOVATOR IN TREATMENT OF CARDIAC ARRHYTHMIAS
Adagio Medical, an operating subsidiary of Adagio Medical Holdings, Inc. (NASDAQ:ADGM), is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (UTLC) technology. UTLC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vClas™ catheter, which is CE Marked and is currently under evaluation in the FULCRUM-VT U.S. IDE Pivotal Study.
OUR MISSION
The Adagio Medical, Inc. mission is to be a leading innovator in the treatment of cardiac arrhythmias, committed to improving patient outcomes by developing catheter ablation technologies of uncompromising durability, versatility and safety.
